Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Neurology: Clinical Practice Accelerator
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
    • UDDA Revision Series
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

May 2021; 8 (3) EditorialOpen Access

The Calm Between Storms

Serum Biomarkers in Assessing Interattack Astrocytopathy in Neuromyelitis Optica Spectrum Disorder

Carolyn Goldschmidt, Robert A. Bermel
First published April 9, 2021, DOI: https://doi.org/10.1212/NXI.0000000000000988
Carolyn Goldschmidt
From the Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
DO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Robert A. Bermel
From the Mellen Center for MS Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland, Ohio.
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
The Calm Between Storms
Serum Biomarkers in Assessing Interattack Astrocytopathy in Neuromyelitis Optica Spectrum Disorder
Carolyn Goldschmidt, Robert A. Bermel
Neurol Neuroimmunol Neuroinflamm May 2021, 8 (3) e988; DOI: 10.1212/NXI.0000000000000988

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
502

Share

  • Article
  • Info & Disclosures
Loading

Cytoskeletal structural proteins, released when cellular damage occurs, are biomarker candidates under investigation for many neurologic diseases. Among the potential markers, neurofilament light chain (NfL), expressed in neurons, and glial fibrillary acidic protein (GFAP), expressed in astrocytes, can now be measured in the serum (sNfL and sGFAP) thanks to advances in highly sensitive analytic methodologies, with strong correlation to CSF levels. Early studies of sNfL and sGFAP in MS and neuromyelitis optica spectrum disorder (NMOSD) focus on potential roles as biomarkers of treatment response, risk for relapse, and risk for disability progression.1,-,4 Not surprisingly, levels of sGFAP increase during NMOSD relapses, as the disease process is primarily an astrocytopathy mediated by AQP4-IgG.4,5 More complex questions include how these levels change in between relapses, during disease stability, and if this could be useful in determining treatment response, predicting disability progression, or guiding therapy.

In this issue of Neurology: Neuroimmunology and Neuroinflammation, Hyun et al describe their study measuring sGFAP and sNfL in both participants with active and stable NMOSD and healthy controls. They found that sGFAP and sNfL levels were significantly elevated during clinical attacks, but quickly decreased to interattack levels that were below the cutoff value, which was determined during the study using the healthy controls.6 This trend was steeper for sGFAP levels compared with sNfL. An important feature of the Hyun study is that all 20 participants with NMOSD were treated with rituximab using a standard protocol for the duration of follow-up. The authors conclude that subclinical astrocyte damage, as measured by sGFAP, rarely occurs during interattack periods in individuals with treated NMOSD.

This result is somewhat in contrast to results of a recent study by Wantanabe et al, which found that both sNfL and sGFAP levels were higher in participants with NMOSD than healthy controls, even during disease remission; however, in a more heterogeneous study group, some of whom were not on any treatment.4 Additional challenges of comparing across studies relate to the technical features of assays, which are pushing the limits of detection to achieve sufficient sensitivity to reliably measure these proteins in the peripheral blood.

Important limitations of the Hyun study are that we cannot tell if sampling more frequently than every 3 months would detect interattack subclinical elevations in sGFAP or more accurately characterize the beginning of an attack. The study used retrospectively assigned Expanded Disability Status Scale scores via chart review, which is not likely the most accurate or sensitive measure of clinical status. The results should only be generalized to patients on treatment with rituximab. The population studied is exclusively Korean, and conceivably phylogenetic differences could lead to different disease behavior in different populations.

The clinical course of NMOSD would suggest that there is not strong evidence for a progressive, degenerative phase of the disease independent of relapses, like is seen in MS, although data are mixed.7,-,9 It would be reasonable to surmise therefore that large amounts of subclinical damage do not occur between attacks. However, as our imaging and laboratory measurement capabilities advance and our range of therapeutic options expand, there may be value in detecting and controlling interattack disease activity if it can be appreciated at a cellular level and its consequences defined. For now, it is useful to be able to visualize the stability of these biomarkers in between relapses and their significant increase during relapses.

Studies such as this represent important milestones in the search for accessible serum biomarkers of disease activity or response to therapy in NMOSD. The promise of using serum biomarkers to potentially predict NMOSD relapses before clinical manifestations certainly has appeal. Previous studies have shown that sNfL levels increase just before clinical events in MS, and it is known that sNFL and sGFAP are greatly elevated during acute NMOSD attacks.5,10 In NMOSD, the utility of predictive biomarkers is particularly appealing. Even with early accurate diagnosis and effective preventive therapy, disabling relapses remain all too common in NMOSD. MRI surveillance does not effectively identify subclinical disease activity; therefore, imaging monitoring for disease activity outside of clinical attacks is challenging. The ability to predict and preempt a relapse, with an even lower threshold to escalate treatment if needed, could change the NMOSD disease course and potential disability accrual. For this task, measurement of cytoskeletal elements alone may be insufficient, and discovery of such biomarkers may require looking at other immunologic or cellular modulators of disease activity. Because of the devastating and permanent disability that can accompany NMOSD attacks, the potential benefit of overtreatment outweighs the risk of undertreating this disease. One blood draw per month to potentially preserve vision or mobility could be a game changer.

Study Funding

No targeted funding reported.

Disclosure

R. Bermel has served as a consultant for Biogen, EMD Serono, Genzyme/Sanofi, Genentech/Roche, Novartis, and Viela Bio. He receives ongoing research support directed to his institution from Biogen, Genentech, and Novartis. C. Goldschmidt has no disclosures. Go to Neurology.org/NN or full disclosures.

Footnotes

  • Go to Neurology.org/NN or full disclosures. Funding information is provided at the end of the article.

  • See page e965

  • Received February 1, 2021.
  • Accepted in final form February 24, 2021.
  • Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Canto E,
    2. Barro C,
    3. Zhao C, et al
    . Association between serum neurofilament light chain levels and long-term disease course among patients with multiple sclerosis followed up for 12 years. JAMA Neurol 2019;76(11):1359–1356.
    OpenUrl
  2. 2.↵
    1. Kapoor R,
    2. Smith KE,
    3. Allegretta M, et al
    . Serum neurofilament light as a biomarker in progressive multiple sclerosis. Neurology 2020;95(10):436–444.
    OpenUrl
  3. 3.↵
    1. Manouchehrinia A,
    2. Stridh P,
    3. Khademi M, et al
    . Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis. Neurology 2020;94(23):e2457–e2467.
    OpenUrl
  4. 4.↵
    1. Watanabe M,
    2. Nakamura Y,
    3. Michalak Z, et al
    . Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD. Neurology 2019;93(13):e1299–e1311.
    OpenUrl
  5. 5.↵
    1. Takano R,
    2. Misu T,
    3. Takahashi T,
    4. Sato S,
    5. Fujihara K,
    6. Itoyama Y
    . Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology 2010;75(3):208–216.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Hyun JW,
    2. Kim Y,
    3. Kim SY,
    4. Lee MY,
    5. Kim SH,
    6. Kim HJ
    . Investigating the presence of inter-attack astrocyte damage in NMOSD: longitudinal analysis of serum GFAP. Neurol Neuroimmunol Neuroinflamm 2021;8(3):e965. doi: 10.1212/NXI.0000000000000965.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Wingerchuk DM,
    2. Pittock SJ,
    3. Lucchinetti CF,
    4. Lennon VA,
    5. Weinshenker BG
    . A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 2007;68(8):603–605.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Pisa M,
    2. Ratti F,
    3. Vabanesi M, et al
    . Subclinical neurodegeneration in multiple sclerosis and neuromyelitis optica spectrum disorder revealed by optical coherence tomography. Mult Scler 2020;26(10):1197–1206.
    OpenUrlPubMed
  9. 9.↵
    1. Kawachi I,
    2. Lassmann H
    . Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 2017;88(2):137–145.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Bjornevik K,
    2. Munger KL,
    3. Cortese M, et al
    . Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol 2020;77(1):58–64.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. [email protected]
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study Funding
    • Disclosure
    • Footnotes
    • References
  • Info & Disclosures
Advertisement

Hastening the Diagnosis of Amyotrophic Lateral Sclerosis

Dr. Brian Callaghan and Dr. Kellen Quigg

► Watch

Related Articles

  • Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum DisorderLongitudinal Analysis of Serum Glial Fibrillary Acidic Protein

Topics Discussed

  • Devic's syndrome

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Article
    Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD
    Mitsuru Watanabe, Yuri Nakamura, Zuzanna Michalak et al.
    Neurology, August 30, 2019
  • Article
    Investigating the Presence of Interattack Astrocyte Damage in Neuromyelitis Optica Spectrum Disorder
    Longitudinal Analysis of Serum Glial Fibrillary Acidic Protein
    Jae-Won Hyun, Yeseul Kim, So Yeon Kim et al.
    Neurology: Neuroimmunology & Neuroinflammation, April 09, 2021
  • Article
    Serum biomarkers in myelin oligodendrocyte glycoprotein antibody–associated disease
    Hyunjin Kim, Eun-Jae Lee, Seungmi Kim et al.
    Neurology: Neuroimmunology & Neuroinflammation, March 17, 2020
  • Article
    Pregnancy in Patients With AQP4-Ab, MOG-Ab, or Double-Negative Neuromyelitis Optica Disorder
    Nicolas Collongues, Cecilia Alves Do Rego, Bertrand Bourre et al.
    Neurology, February 24, 2021
Neurology - Neuroimmunology Neuroinflammation: 11 (1)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise